P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific community, leading to the development, investigation, and authorization of vaccines and …
The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …
T Majerová, J Konvalinka - Molecular aspects of medicine, 2022 - Elsevier
Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and herpesviruses―code for a protease, which is indispensable for viral maturation and …
J Ceramella, D Iacopetta, MS Sinicropi, I Andreu… - Molecules, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …
D Marangoni, RM Antonello, M Coppi… - International Journal of …, 2023 - Elsevier
Immunocompromised patients still experience unpredictable courses of COVID-19, despite that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …
K Rosenke, MC Lewis, F Feldmann, E Bohrnsen… - JCI insight, 2023 - ncbi.nlm.nih.gov
The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable clinical severity and ability to escape preexisting immunity emphasizes the continued need …
A Gidari, S Sabbatini, E Schiaroli, S Bastianelli… - Viruses, 2023 - mdpi.com
Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and …
A Zibat, X Zhang, A Dickmanns, KM Stegmann… - Iscience, 2023 - cell.com
Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …
DM Johnson, T Brasel, S Massey, T Garron, M Grimes… - Antiviral research, 2023 - Elsevier
Abstract Molnupiravir (EIDD-2801) is a prodrug of a ribonucleoside analogue that is currently being used under a US FDA emergency use authorization for the treatment of mild …